FDA Inspection 1255806 — Zhejiang Haisen Pharmaceutical Co., Ltd.
The FDA completed an inspection of Zhejiang Haisen Pharmaceutical Co., Ltd. on November 15, 2024 in Dongyang. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- November 15, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Dongyang (China)